Go to the exam! shengnuo biotechnology will be reviewed on the scientific innovation board on December 11
On December 3, capital state learned that the stock listing committee of Shanghai Stock Exchange science and Technology Innovation Board will hold the 117th and 118th listing committee review meetings in 2020 at 9:00 a.m. and 13:00 p.m. on December 11, 2020. At that time, four companies, Chengdu Shengnuo Biotechnology Co., Ltd.
(hereinafter referred to as: sinobio), Jiangsu maixinlin Aviation Technology Co., Ltd. (hereinafter referred to as: maixinlin), Beijing Xin’an Century Technology Co., Ltd. (hereinafter referred to as Xin’an century) and Xi’an Kangtuo Medical Technology Co., Ltd. (hereinafter referred to as Kangtuo medical) will be audited.
shengnuo biotechnology is a high-tech enterprise with the core technology of peptide synthesis and modification.
Its main business includes providing pharmaceutical research and customized production services for domestic and foreign pharmaceutical enterprises in the research and development of polypeptide innovative drugs,
independent research and development, production and sales of polypeptide generic drug raw materials and preparation products with large market capacity and strong competitiveness at home and abroad, as well as peptide drug production Technology transfer services. From 2017 to the first half of 2020,
the company’s revenue was 194 million yuan, 278 million yuan, 327 million yuan and 176 million yuan respectively; the corresponding net profits in the same period were 33.9004 million yuan, 29.8613 million yuan, 48.1317 million yuan and 31311.11 million yuan respectively.